目的 評價肝復樂膠囊聯(lián)合索拉非尼治療晚期肝癌的臨床療效。方法 選取2014年5月—2016年5月在中國人民解放軍總醫(yī)院第一附屬醫(yī)院接受治療的晚期肝癌患者80例，根據(jù)治療方案的差別分成對照組（40例）和治療組（40例）。對照組患者口服甲苯磺酸索拉非尼片，0.4 g/次，2次/d。治療組在對照組的基礎上口服肝復樂膠囊，6粒/次，3次/d。兩組患者均治療4周。評價兩組患者治療前后近期療效、生存質(zhì)量改善情況和血清學指標差異。結(jié)果 治療后，對照組的客觀緩解率（ORR）為40.00%，臨床獲益率（CBR）為75.00%，治療組的ORR為67.50%，CBR為92.50%，兩組ORR、CBR比較差異均有統(tǒng)計學意義（P < 0.05）。治療后，對照組的生存質(zhì)量改善率為75.00%，顯著低于治療組的92.50%，兩組生存質(zhì)量改善情況比較差異有統(tǒng)計學意義（P < 0.05）。治療后，兩組患者血清血管內(nèi)皮生長因子（VEGF）、缺氧誘導因子-1α（HIF-1α）和骨橋蛋白（OPN）水平均明顯降低，同組治療前后比較差異具有統(tǒng)計學意義（P < 0.05）；且治療后治療組患者降低更明顯，兩組比較差異具有統(tǒng)計學意義（P < 0.05）。結(jié)論 肝復樂膠囊聯(lián)合索拉非尼治療晚期肝癌的臨床療效較好，可以提高患者免疫能力和改善生活質(zhì)量，具有一定的臨床推廣應用價值。

Objective To evaluate the clinical effect of Ganfule Capsules combined with sorafenib in treatment of advanced liver cancer. Methods Patients (80 cases) with advanced liver cancer in First Affiliated Hospital of PLA General Hospital from May 2014 to May 2016 were divided into control (40 cases) and treatment (40 cases) groups according to different treatments. Patients in the control group were po administered with Sorafenib Tosylate Tablets, 0.4 g/time, twice daily. Patients in the treatment group were po administered with Ganfule Capsules on the basis of the control group, 6 grains/time, three times daily. Patients in two groups were treated for four weeks. After treatment, the differences of the clinical efficacy, short-term efficacy, quality of life, and serological indexes in two groups were evaluated. Results ORR and CBR in the control group were 40.00% and 75.00% respectively, and ORR and CBR in the treatment were 67.50% and 92.50% respectively, and there were differences between two groups (P < 0.05). After treatment, the improvement rate of life quality in the control group was 75.00%, which was significantly lower than 92.50% in the treatment group, with significant difference between two groups (P < 0.05). After treatment, the serum VEGF, HIF-1α, and OPN levels in two groups significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And these serological indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Ganfule Capsules combined with sorafenib has a good clinical curative effect in treatment of advanced liver cancer, can improve the immune ability and the quality of life, which has a certain clinical application value.